Barclays Appoints Naeem Merchant as a Managing Director in Healthcare Investment Banking

Barclays announces the appointment of Naeem Merchant as a Managing Director in Healthcare Investment Banking. Mr. Merchant will be based in New York, and will focus on the Pharmaceutical Services and IT sectors. He will report to Rick Landgarten, Global Head of Healthcare & Real Estate Groups at Barclays.

Recommended AI News: Two in Three Banks Expect to Lose Market Share Unless They Embrace Digitisation

“Naeem’s appointment is further evidence of our dedication to investing in top level talent in order to enable us to continue to build on our successes and strong momentum in our Healthcare franchise.”

Mr. Merchant joins Barclays from Greenhill & Co. where he was a Managing Director focused on Pharmaceutical Services. He started his investment banking career at Lehman Brothers fourteen years ago. Mr. Merchant has led the origination and execution of a number of high-profile transactions during his career. He has deep domain expertise, and strategic and investor relationships, across the Pharmaceutical Services and IT sectors, including providers of technology and services supporting pharmaceutical research and development, manufacturing and distribution, and commercialization.

Recommended AI News: Outseer Protects $100 Billion In Payment Transactions Year-To-Date Via 3-D Secure

“We are delighted to welcome Naeem back to Barclays and to our Healthcare team. His deep industry relationships and extensive transactional experience will generate tremendous value for our clients,” said Rick Landgarten, Global Head of Healthcare & Real Estate Groups. “Naeem’s appointment is further evidence of our dedication to investing in top level talent in order to enable us to continue to build on our successes and strong momentum in our Healthcare franchise.”

Barclays has performed lead roles in a number of recent transactions of note in the Healthcare Banking space, including serving as financial advisor to Thermo Fisher Scientific on their pending $21bn acquisition of PPD, and acting as financial advisor to Centene Corporation in the company’s $3.1bn acquisition of Magellan Health, Inc. Barclays acted as financial advisor to Kindred at Home on their sale to Humana, and served as financial advisor to HMS on the company’s sale to Veritas Capital-backed Gainwell Technologies for $3.4bn. In addition, Barclays has performed key roles in several recent IPOs of note, including serving as a senior active bookrunner on a $649mm IPO for Signify Health, Inc., as an active bookrunner on a $924mm IPO for Bright Health Group, Inc., and as an active bookrunner on a $1.3bn IPO for GoodRx Holdings, Inc.

Recommended AI News: Stensul Email Creation Platform Adds Integrations with Microsoft Teams and Slack

[To share your insights with us, please write to sghosh@martechseries.com ]